Fate Therapeutics CEO Scott Wolchko retiring and Bob Valamehr taking over as CEO

From Nasdaq: 2024-11-29 22:26:44

Fate Therapeutics Inc. announced that its President and CEO, Scott Wolchko, will retire on December 31, 2024. Bob Valamehr, the current President of R&D, will take over as President and CEO starting January 1, 2025. Dr. Valamehr has been leading the development of the Company’s iPSC platform for nearly 15 years.



Read more at Nasdaq: Fate Therapeutics CEO Scott Wolchko To Retire; Names Bob Valamehr CEO